Kurin, Inc. Files False Advertising Lawsuit Against ICU Medical and Vascular Integrity

Kurin, Inc. announced that it filed a lawsuit against ICU Medical, Inc. and Vascular Integrity, LLC for making false and misleading clinical performance claims regarding the Vascular Integrity Bypass Syringe. The lawsuit was filed on March 15, 2024, in the US District Court, Central District of California. The syringe is manufactured by Vascular Integrity and ICU Medical is the distributor of this product.

“Kurin is the market leader in the blood culture contamination device market and our success is no doubt observed by others wondering how they might take advantage of the interest we have generated,” said Bob Rogers, Inventor and CEO of Kurin. “In this case, misleading claims that the Bypass Syringe reduces blood culture contamination, CLABSIs, and hemolysis are not supported in the regulatory documents. These statements are not only misleading, hospitals believing these claims could actually cause patient harm.”

“We filed this suit because Defendants ignored our friendly notice of these unsupported claims. Given their inattention to this matter, litigation was our only avenue to address these misleading statements.”

Kurin’s revolutionary approach to the contaminated blood culture problem is an elegantly simple, intuitive design that requires no additional user steps. Kurin passively sidelines potential contaminants during blood culture collection. Kurin is a simply better and more sustainable approach over conventional mechanical diversion. Contaminated blood cultures are a significant problem, as roughly one-third of the positive results are wrong, exposing these patients to unnecessary antibiotics, extending hospital stays and impacting larger community health issues, such as antimicrobial resistance and life-threatening C. diff. infections. Kurin Lock and Kurin Jet give clinicians the tools they need to address these problems.

About Kurin, Inc.

Kurin Inc., a certified Minority Business Enterprise (MBE), is focused on the design, development, manufacture, marketing, and sale of products that help healthcare providers reduce contaminated blood cultures. San Diego-based Kurin has received FDA 510(k) market clearance. For more information, visit the website at www.kurin.com.